Access to appropriate pain treatment is a basic human right. As a leader in pain management, we help to educate healthcare professionals and patients about how to use medicines responsibly. We also raise awareness and increase the accessibility of current treatments while developing new medicines for unmet medical needs.
Grünenthal’s focus on patients is the core of our sustainability approach. Our four key material topics directly support our vision of a World Free of Pain.
This approach is built on three pillars that form the basis of our business relationships: strict governance, close involvement of our business partners, and education about pain medication for healthcare professionals and patients.
| Our sustainability ambitions |
| Continuous development and improvement of Grünenthal’s Opioid Responsibility Framework. |
| Continuous expansion of the network of business partners that have committed to our Opioid Responsibility Framework for Business Partners. |
| Further expansion of the CHANGE PAIN™ (CP) hub, ‘CP Responsibly’, featuring Grünenthal and independent Responsible Use of Pain Medication educational resources. |
|
Postponed launch of an educational expert forum on Responsible Use of Pain Medication in Latin America from the end of 2022 to end of 2024 (with a pilot to bridge until then), to be recognised as the platform for Responsible Use of Pain Medication by international healthcare professionals by the end of 20261 1 We are currently shifting towards being more customer centric across the organisation. We are embedding set-up of the Expert Forum in the change process and are therefore delaying its go-live. |
We have a longstanding tradition of educating healthcare professionals about pain management to deepen understanding of patients’ needs, as well as the risks and benefits of pain medication. This Impact Initiative places an even stronger focus on this topic.
visitors to our educational websites about pain management in 2022.
Patients in pain need access to appropriate pain treatments. We believe responsibly prescribed opioids should be one of the options available. However, while opioids can provide benefits for patients in pain, they may also carry risks. These risks include inappropriate use, misuse, abuse and diversion, as well as the risk of addiction. That is why it is essential that physicians prescribe opioids after careful consideration of the benefits and risks, and that they evaluate all available treatment options.
Our Opioid Statement is a one-page document that clearly highlights the risks and benefits of this class of medicines. We use this statement in all materials related to opioids. It clarifies our position for all of our stakeholders and aims to foster a mindset shift along the entire value chain.
Link to statementOur Opioid Charter underpins Grünenthal’s position about the responsible medical use of opioid analgesics in pain patients. Our Strategic Committee on Responsible Opioid Usage ensures clear guidance, coherent behaviour, continuous improvement, training and control mechanisms.
Download infographicThe Opioid Communication Guidance defines principles that apply to all promotional content for these pain treatments. It places a strong focus on ethical responsibilities related to opioid usage.
Raising awareness and enabling access to pain medication are core focus areas for us. We aim to ensure that pain is acknowledged as a disease in its own right, and we want to ensure access to appropriate medicines that treat pain. We strive to raise awareness and accessibility through a diverse range of initiatives within one holistic awareness and accessibility platform with three pillars: A global governance structure, globally aligned content and formats, and a roll-out plan that focuses on communication and training.
| Our sustainability ambitions |
| Increase the focus, reach and impact of our global and local activities for Awareness & Accessibility by aligning them strategically under one global platform. |
| By having a clear strategy regarding governance, transparency and accountability, we ensure that our Awareness & Accessibility initiatives have a lasting impact on patients’ lives. |
| Use our global network to collaborate with external partners to identify best leverage opportunities for our unique expertise to have a lasting impact on improving pain management. |
The mission of our Awareness & Accessibility Impact Initiative is to positively impact patients’ lives by improving access to adequate pain management, as well as raising awareness about chronic pain and palliative care.
Chronic pain and palliative care are two areas with a clear need for improved education, increased awareness and better access to appropriate treatment – everywhere in the world. Read more about the impact of chronic pain in our section Understanding Pain.
invested worldwide in awareness and accessibility initiatives in 2022.
We aim to strengthen our pain leadership by developing highly innovative, non-opioid therapies. Two recent examples:
The Foundation’s achievements include facilitating the creation of the Department of Palliative Medicine at the Aachen University Hospital in 2003 – the first of its kind in Germany.
Today, close to 20 chairs and professorships in palliative medicine and paediatric palliative medicine exist in Germany.
In Peru, our work supports a master’s degree in Palliative Medicine and Pain Management at the Universidad Nacional Mayor de San Marcos. Launched in 2018, it is the country’s first academic programme in this field. Almost 100 professionals have now graduated and are creating palliative care units across Peru.
Despite many years of scientific research, not all pain can be adequately treated. Our R&D experts are dedicated to finding solutions for unmet needs.
| Our sustainability ambitions |
| Reducing cycle time and resources required for de novo candidate discovery through machine learning (ML) (baseline 18 months; goal in 2025, 14 months). |
| Improving clinical trial design through ML-based patient phenotyping (baseline 0 trials; goal in 2025, 2 trials). |
| Improving understanding of treatment effects in clinical studies and post-approval through objective measurement of mobility and sleep (baseline 1 study; goal in 2025, 2 studies). |
With this Impact Initiative, Grünenthal aims to build data-driven human disease understanding along the R&D value chain and to enhance our ability to create truly novel medicines for patients in need.
We need solutions that address huge unmet needs in pain management. Through our funding programmes such as the EFIC-Grünenthal Grant, the Brain Mind Pain Patient Grant, IMI PainCare, MOBILISE-D and ESCulab, we support scientists in carrying out innovative clinical pain research. We have more than 250 priority patent applications.
Our products are made to manage pain. High standards for safety and quality are essential.
| Our sustainability ambitions |
| 97% ‘on-time’ submissions to authorities worldwide for Individual Case Safety Reports (ICSRs). |
| Maintain or exceed the current level of recognised compliance with global pharmacovigilance standards. |
| 100% compliance with the International Conference on Harmonisation-Good Clinical Practice (ICHGCP) standards and other applicable ethical standards. |
of 1,018 employees at our headquarters completed pharmacovigilance training via eLearning within the last 12-month cycle.
external quality certifications awarded to Grünenthal’s manufacturing facilities.
of Individual Case Safety Reports (ICSRs) conducted on time for health authorities in Europe and Latin America.
M-N/A-DE-08-23-0003